News Feed Item

Tumor Profiling Studies on Difficult-to-Treat Gastrointestinal Cancers Aid in Development of Personalized Treatment Planning

Research uncovers clinically actionable biomarker targets and key treatment insights for colorectal, gastric, neuroendocrine and appendiceal cancer patients

IRVING, Texas, Jan. 16, 2014 /PRNewswire/ -- Caris Life Sciences®, a leading biosciences company focused on fulfilling the promise of personalized medicine, will present multiple tumor profiling studies at the 2014 Gastrointestinal Cancers Symposium held this week in San Francisco, Calif. This research demonstrates the impact of Caris Molecular Intelligence,™ the company's comprehensive tumor profiling service, on improving care for patients with difficult-to-treat and/or rare and aggressive tumor types, including colorectal, gastric, neuroendocrine and appendiceal cancers.  These studies also highlight the importance of the company's unique multi-technology approach to tumor profiling, which identifies clinically relevant alterations beyond DNA sequencing alone.

"In rare tumor types, access to molecularly-guided therapies is imperative, as these patients have fewer standard treatments available to them," said Zoran Gatalica, M.D., DSc, Executive Medical Director at Caris Life Sciences. "In our study of neuroendocrine cancer, we found clinically relevant drug targets in 90 percent of patients profiled, and our study of appendiceal cancer may point the way to a new paradigm in how therapies are prescribed for this disease. These are clear indications of the critical role tumor profiling plays in expanding therapeutic options for these patients."

The company's neuroendocrine cancer study profiled tumors in collaboration with Fox Chase Cancer Center. The study describes two examples where patients experienced extraordinary responses to Caris-directed treatments, highlighting the power of personalized medicine in the treatment of rare and aggressive cancers.   Alterations in the expression of three proteins and one somatic mutation were used to identify the effective treatment in the first patient, while the treatment for the second patient was identified through an alteration of expression of just one protein not generally measured in this type of cancer. 

The second Caris study profiled appendiceal cancer and was completed in collaboration with Translational Genomics Research Institute - Virginia G Piper Cancer Center.   This is the first report of a near universal alteration in appendiceal cancer of a protein associated with approved therapies in other indications.  These findings suggest appendiceal cancer patients may benefit from neo-adjuvant treatment with drugs commonly used to treat other cancer types.  This study demonstrates how comprehensive profiling can provide great clinical value by illuminating potentially beneficial treatment options in a disease without any randomized clinical trials providing established standard-of-care guidelines.

The third Caris study, in collaboration with Comprehensive Cancer Centers of Nevada, focused on colorectal cancer, examining alterations in the EGFR signaling pathway. This study found that only approximately 20 percent of KRAS wild type patients did not harbor an aberration in the EGFR signaling pathway, potentially explaining why 80 percent of KRAS wild type patients do not respond to EGFR- targeted therapies.  

Additionally, the Division of Surgical Oncology, Medical College of Wisconsin, is presenting a fourth poster describing an independent validation of the clinical utility of Caris Molecular Intelligence in gastric cancer. This study will report that approximately 93 percent of gastric cancer patients profiled had alternations in one of three proteins correlated with sensitivity to at least one chemotherapy agent.

A schedule of presentations is as follows:

Friday, Jan. 17, 2014
Poster Presentations

  • Abstract 214: Igor A. Astsaturov, Steven J. Cohen, Paul F. Engstrom, et al. Profiling of a global cohort of 1,250 neuroendocrine tumors to identify multiple potential drug targets. BRD: A43, Session B.
  • Abstract 131: John T. Miura, Thejus Jayakrishnan, Dan Eastwood, et al. Molecular profiling in gastric cancer: Examining potential targets for chemotherapy. BRD: D37, Session B

Saturday, Jan. 18, 2014
Poster Presentations

  • Abstract 399: Gargi D. Basu, Joanne Xiu, David Arguello, et al. Prevalence of KRAS, BRAF, NRAS, PIK3CA and PTEN alterations in colorectal cancer: Analysis of a large international cohort of 5,900 patients . BRD: A18, Session C
  • Abstract 469: Erkut Borazanci, Jeffery Kimbrough, Jasgit C. Sachdev, et al. Potential actionable targets in appendiceal cancer detected by immunohistochemistry (IHC), fluorescent in situ hybridization (FISH) and mutational analysis. BRD: B32, Session C

About Caris Molecular Intelligence

Caris Molecular Intelligence™ has been the leading cancer profiling service on the market since 2006, having been used for more than 60,000 cancer patients and counting by more than 6,000 oncologists in at least 59 countries to help develop individualized and actionable treatment plans that seek to improve patient care.  Caris Molecular Intelligence™ utilizes the most comprehensive range of analytical technologies endorsed by the latest and most robust evidence — immunohistochemistries, fluorescence and chromogenic in situ hybridization, polymerase chain reaction and Next-Generation sequencing – to provide oncologists the most complete and clinically relevant profile of a patient's unique cancer-related biomarkers. Unlike other commercially available tumor profiling services, Caris Molecular Intelligence™ more completely interrogates a patient's unique tumor biology by going beyond just DNA analysis. Caris' service assesses additional important biological components like RNA and protein expression levels to establish a multi-dimensional profile of a patient's tumor that reveals more fully the complex biological processes that are driving that patient's cancer and, therefore, more, relevant targets for potential clinical action. 

With a multi-dimensional profile of a patient's unique tumor, Caris Molecular Intelligence integrates insights from its proprietary and industry-leading evidence curation and bioinformatics platform to identify and report the most clinically relevant associations to drug therapies that are approved by the U.S. Food & Drug Administration or are in active clinical trials in the U.S. Managed by the Caris Evidence Design Board, a dedicated team of oncology experts that includes 5 Ph.D.s and 6 M.D.s, the Caris Molecular Intelligence evidence and bioinformatics platform curates, classifies and catalogues the findings and evidence from all relevant clinical studies in cancer and cancer biology available in the published scientific and medical literature, using a methodology adapted from the evidence review process of U.S. Preventive Services Task Force (www.uspreventiveservicestaskforce.org) of the Agency for Health Research and Quality (www.ahrq.gov).  This platform incorporates the review of more than 100,000 publications and counting.  Relying on the most robust evidence that meets Caris' quality standards, the Caris Molecular Intelligence evidence and bioinformatics platform can currently provide therapeutic guidance for up to 43 drug associations with Caris' multi-dimensional approach to tumor profiling, far exceeding the 12 that can be identified using next-generation sequencing alone.  The Caris Molecular Intelligence bioinformatics platform electronically delivers the profile and all of these results in an easy-to-use report format that gives oncologists access to underlying evidence, enabling them to develop tailored treatment plans for each unique patient. For more information on Caris Molecular Intelligence™, visit www.carismolecularintelligence.com.

About Caris Life Sciences

Caris Life Sciences is a leading biosciences company focused on fulfilling the promise of personalized medicine.  As the first commercial mover in comprehensive molecular profiling in oncology, Caris Molecular Intelligence™ is an industry vanguard, with 60,000-plus patients profiled and counting. Ordered by nearly 6,000 oncologists in 59 countries, Molecular Intelligence correlates molecular data generated from a patient's tumor with biomarker/drug associations derived from clinical cancer literature. Using a variety of advanced and clinically-relevant technologies, Caris provides oncologists with the most clinically actionable information to help them personalize treatment for cancer patients. This multi-technology approach enables Caris to provide therapeutic guidance for 43 drug associations, compared to the 12 that can be found through use of next-generation sequencing alone. The company is also developing a series of blood tests based on its proprietary Carisome® platform — a revolutionary blood-based testing technology for diagnosis, prognosis, and theranosis of cancer and other complex diseases. Headquartered in Irving, Texas, Caris Life Sciences offers services throughout the U.S., Europe, Australia and other international markets. To learn more, please visit www.carislifesciences.com.

SOURCE Caris Life Sciences

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
More and more brands have jumped on the IoT bandwagon. We have an excess of wearables – activity trackers, smartwatches, smart glasses and sneakers, and more that track seemingly endless datapoints. However, most consumers have no idea what “IoT” means. Creating more wearables that track data shouldn't be the aim of brands; delivering meaningful, tangible relevance to their users should be. We're in a period in which the IoT pendulum is still swinging. Initially, it swung toward "smart for smar...
So you think you are a DevOps warrior, huh? Put your money (not really, it’s free) where your metrics are and prove it by taking The Ultimate DevOps Geek Quiz Challenge, sponsored by DevOps Summit. Battle through the set of tough questions created by industry thought leaders to earn your bragging rights and win some cool prizes.
Manufacturers are embracing the Industrial Internet the same way consumers are leveraging Fitbits – to improve overall health and wellness. Both can provide consistent measurement, visibility, and suggest performance improvements customized to help reach goals. Fitbit users can view real-time data and make adjustments to increase their activity. In his session at @ThingsExpo, Mark Bernardo Professional Services Leader, Americas, at GE Digital, discussed how leveraging the Industrial Internet a...
SYS-CON Events announced today that LeaseWeb USA, a cloud Infrastructure-as-a-Service (IaaS) provider, will exhibit at the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. LeaseWeb is one of the world's largest hosting brands. The company helps customers define, develop and deploy IT infrastructure tailored to their exact business needs, by combining various kinds cloud solutions.
A completely new computing platform is on the horizon. They’re called Microservers by some, ARM Servers by others, and sometimes even ARM-based Servers. No matter what you call them, Microservers will have a huge impact on the data center and on server computing in general. Although few people are familiar with Microservers today, their impact will be felt very soon. This is a new category of computing platform that is available today and is predicted to have triple-digit growth rates for some ...
Effectively SMBs and government programs must address compounded regulatory compliance requirements. The most recent are Controlled Unclassified Information and the EU’s GDPR have Board Level implications. Managing sensitive data protection will likely result in acquisition criteria, demonstration requests and new requirements. Developers, as part of the pre-planning process and the associated supply chain, could benefit from updating their code libraries and design by incorporating changes.
November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Penta Security is a leading vendor for data security solutions, including its encryption solution, D’Amo. By using FPE technology, D’Amo allows for the implementation of encryption technology to sensitive data fields without modification to schema in the database environment. With businesses having their data become increasingly more complicated in their mission-critical applications (such as ERP, CRM, HRM), continued ...
SYS-CON Events announced today that Cloudbric, a leading website security provider, will exhibit at the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Cloudbric is an elite full service website protection solution specifically designed for IT novices, entrepreneurs, and small and medium businesses. First launched in 2015, Cloudbric is based on the enterprise level Web Application Firewall by Penta Security Sys...
SYS-CON Events announced today that SoftNet Solutions will exhibit at the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. SoftNet Solutions specializes in Enterprise Solutions for Hadoop and Big Data. It offers customers the most open, robust, and value-conscious portfolio of solutions, services, and tools for the shortest route to success with Big Data. The unique differentiator is the ability to architect and ...
Most people haven’t heard the word, “gamification,” even though they probably, and perhaps unwittingly, participate in it every day. Gamification is “the process of adding games or game-like elements to something (as a task) so as to encourage participation.” Further, gamification is about bringing game mechanics – rules, constructs, processes, and methods – into the real world in an effort to engage people. In his session at @ThingsExpo, Robert Endo, owner and engagement manager of Intrepid D...
WebRTC adoption has generated a wave of creative uses of communications and collaboration through websites, sales apps, customer care and business applications. As WebRTC has become more mainstream it has evolved to use cases beyond the original peer-to-peer case, which has led to a repeating requirement for interoperability with existing infrastructures. In his session at @ThingsExpo, Graham Holt, Executive Vice President of Daitan Group, will cover implementation examples that have enabled ea...
SYS-CON Events announced today that Enzu will exhibit at the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Enzu’s mission is to be the leading provider of enterprise cloud solutions worldwide. Enzu enables online businesses to use its IT infrastructure to their competitive advantage. By offering a suite of proven hosting and management services, Enzu wants companies to focus on the core of their online busine...
@DevOpsSummit has been named the ‘Top DevOps Influencer' by iTrend. iTrend processes millions of conversations, tweets, interactions, news articles, press releases, blog posts - and extract meaning form them and analyzes mobile and desktop software platforms used to communicate, various metadata (such as geo location), and automation tools. In overall placement, @DevOpsSummit ranked as the number one ‘DevOps Influencer' followed by @CloudExpo at third, and @MicroservicesE at 24th.
In the next forty months – just over three years – businesses will undergo extraordinary changes. The exponential growth of digitization and machine learning will see a step function change in how businesses create value, satisfy customers, and outperform their competition. In the next forty months companies will take the actions that will see them get to the next level of the game called Capitalism. Or they won’t – game over. The winners of today and tomorrow think differently, follow different...
SYS-CON Events announced today that Roundee / LinearHub will exhibit at the WebRTC Summit at @ThingsExpo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. LinearHub provides Roundee Service, a smart platform for enterprise video conferencing with enhanced features such as automatic recording and transcription service. Slack users can integrate Roundee to their team via Slack’s App Directory, and '/roundee' command lets your video conference ...